Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease. (Q48447096)

11 February 2018

title

Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease. (English)

1 reference

11 February 2018

0 references

0 references

1 reference

Mikio Shoji

8

1 reference

ORCID Public Data File 2021

author name string

Asano Asami-Odaka

1

1 reference

11 February 2018

Yuka Obayashi-Adachi

2

1 reference

11 February 2018

Yoshio Matsumoto

3

1 reference

11 February 2018

Hideki Takahashi

4

1 reference

11 February 2018

Hiroaki Fukumoto

5

1 reference

11 February 2018

Takashi Horiguchi

6

1 reference

11 February 2018

Nobuhiro Suzuki

7

1 reference

11 February 2018

publication date

1 January 2005

1 reference

11 February 2018

Neurodegenerative Diseases

published in

1 reference

11 February 2018

volume

2

1 reference

11 February 2018

page(s)

36-43

1 reference

11 February 2018

issue

1

1 reference

11 February 2018

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

cites work

1 reference

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

21 January 2018

1 reference

Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants

21 January 2018

1 reference

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

Cerebral hemorrhage after passive anti-Abeta immunotherapy.

21 January 2018

1 reference

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

21 January 2018

1 reference

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice.

21 January 2018

1 reference

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

21 January 2018

1 reference

Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000086429

1 reference

11 February 2018

PubMed ID

16909001

1 reference

11 February 2018